Corona Remedies IPO Details
The Corona Remedies IPO is a book build issue with a total issue size of ₹655.37 cr, and a offer for sale of 6171101 equity shares. Corona Remedies IPO opened for subscription on Dec 08, 2025 and closed on Dec 10, 2025. Corona Remedies IPO is set price band at ₹1008 to ₹1062 per share, with a lot size of 14 shares. Minimum investment for Retail investors was ₹14,868.00 (at the upper price band) to apply for one lot.
The basis of allotment got finalized on Dec 11, 2025, and listed on both the NSE and BSE on Dec 15, 2025.
Bigshare Services Pvt Ltd has been appointed as the registrar. IIFL Capital Services Limited, JM Financial Limited and Kotak Mahindra Capital Company Limited are the Book Running Lead Manager for the issue.
Before investing in the Corona Remedies IPO, investors should review the company's financial performance, business objectives, and risk factors mentioned in the offer documents and apply before the subscription window closes.
- Price Band
- ₹ 1008 – 1062
- Lot Size
- 14
- Issue Size
- ₹655.37 Cr
- Minimum Investment
- ₹14868 (14 Shares)
- Listing Date
- 15 December 2025
Current GMP
₹342 (+32.20%)
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
About Corona Remedies Limited
Corona Remedies Limited, incorporated in August 2004, is a fast-growing pharmaceutical formulation company focused on the Indian market. The company develops, manufactures, and markets a wide range of branded products across women’s healthcare, cardio-diabeto, pain management, urology, and other key therapeutic segments, including vitamins/minerals/nutrition, gastrointestinal, and respiratory care.
As of December 2024, Corona’s portfolio comprised 67 brands, which expanded to 71 brands by MAT June 2025. Of these, 27 are “engine brands”, contributing over 72% of domestic sales. The company has built strong positions across chronic and sub-chronic therapies, which accounted for 70.10% of domestic revenues and grew at a notable 20.48% CAGR over the period.
Corona has established a strong commercial footprint through a pan-India marketing and distribution network, supported by 2,598–2,671 medical representatives across 22 states, enabling deep engagement with healthcare professionals and robust penetration across its targeted therapy areas. The company ranks 29th in the Indian Pharmaceutical Market (IPM) and 17th in covered markets.
The company operates two manufacturing facilities—one in Gujarat and another in Himachal Pradesh—backed by a strong focus on quality and current Good Manufacturing Practices (cGMP). As of December 31, 2024, Corona employed 88 R&D professionals, underpinning its commitment to developing differentiated pharmaceutical products and strengthening its innovation pipeline. Strategic acquisitions, such as Myoril from Sanofi, have further expanded its specialty portfolio.
Competitive Strengths
- One of the fastest-growing companies among the top 30 IPM players, with a 13.58% CAGR in domestic sales from MAT June 2024 to MAT June 2025, outpacing the IPM growth of 7.90%.
- Proven ability to build a broad, diversified brand portfolio, strengthened by high-performing “engine brands.”
- Extensive pan-India sales infrastructure and a marketing strategy focused on the high-potential “middle of the pyramid” segment.
- Quality-driven manufacturing capabilities and strong R&D focus enabling a pipeline of differentiated formulations.
- Experienced and entrepreneurial leadership team supported by marquee institutional investors.
Corona Remedies IPO Promoters
- Dr. Kirtikumar Laxmidas Mehta
- Niravkumar Kirtikumar Mehta
- Ankur Kirtikumar Mehta
Promoters Holding
Holding Pre Issue
72.50%
Holding Post Issue
0.00%
Corona Remedies IPO Objective
Address / Contact Info
Corona Remedies Limited
CORONA House, C – Mondeal Business Park
Near Gurudwara S. G. Highway
Thaltej Ahmedabad, Gujarat, 380059
Phone: +91 79 4023 3000
Email: complianceofficer@coronaremedies.com
Website: https://www.coronaremedies.com/
IPO Snapshot
Book Running Lead Managers
- IIFL Capital Services Limited
- JM Financial Limited
- Kotak Mahindra Capital Company Limited
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
Corona Remedies IPO is a Book-building IPO with a total issue size of ₹655.37 crore. The Corona Remedies IPO price band is ₹1008 to 1062 per share. The Corona Remedies IPO subscription opens on Mon, Dec 8, 2025, and closes on Wed, Dec 10, 2025. The Corona Remedies IPO will be listed on the BSE,NSE. Bigshare Services Pvt Ltd is the registrar for the Corona Remedies IPO.
The Corona Remedies IPO opens on Mon, Dec 8, 2025 and closes on Wed, Dec 10, 2025
Corona Remedies IPO Price Band is ₹1008 to 1062 per share.
Corona Remedies IPO lot size is 14 shares, Retail investors need a minimum investment of ₹14868 based on the upper price band
The minimum investment for Corona Remedies IPO is ₹14868, based on one lot of 14 shares at the upper price band of ₹1062 per share.
Investors can apply for the Corona Remedies IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Wed, Dec 10, 2025. The application amount remains blocked until the Corona Remedies IPO allotment is finalized.
Corona Remedies IPO issue size is ₹655.37 crores.
Corona Remedies IPO allotment date is Wed, Jul 1, 2026.
The registrar for Corona Remedies IPO is Bigshare Services Pvt Ltd. Investors can go to Bigshare Services Pvt Ltd website to check Corona Remedies IPO allotment status, refund processing, and other IPO-related information.
The Corona Remedies IPO GMP (Grey Market Premium) is ₹342 as of Mon, Dec 15, 2025. Based on the upper price band of ₹1062 per share, the estimated Corona Remedies IPO listing price is ₹1404, indicating a potential listing gain of approximately 0% over the issue price.